Griseovin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Griseovin

Quick Facts

Property Description
Active ingredient Griseofulvin
Form Tablet, Oral Suspension
Pharmacological class Antifungal, Antimycotic agent
Common purpose Systemic treatment of fungal infections
Origin Antifungal antibiotic (derived from Penicillium species)

What Type of Medicine is Griseovin (Griseofulvin)?

Griseovin is a specific trade name for the active ingredient Griseofulvin, classified as a systemic agent belonging to the Antifungal and Antimycotic agent pharmacological classes. The Griseofulvin compound is uniquely sourced as an antifungal antibiotic, reflecting its origin as a secondary metabolite isolated from a species of the Penicillium fungus. This systemic nature ensures that the medication is designed to be absorbed internally, effectively treating fungal pathogens that are inaccessible to topical applications, a method clinically recognized for addressing deeply rooted infections.

Composition and Available Drug Forms

Griseovin is manufactured as a single-ingredient product, containing only crystalline Griseofulvin, with two principal formulations serving as key differentiators: the standard Microsize particle formulation and the specialized Ultramicrosize particle formulation. The latter features a reduced particle size intended to optimize absorption. For oral administration, the drug is supplied in the Dosage forms of a Tablet and an Oral Suspension, with the liquid format often utilized for paediatric patient groups to aid swallowing.

General Therapeutic Purpose and Benefit

The essential therapeutic purpose of Griseofulvin is to address systemic fungal infections by functioning as a fungistatic agent, meaning it arrests the growth and proliferation of fungal organisms. The unique benefit of this Antimycotic agent stems from its physiological action of binding selectively to keratin precursor cells after oral administration. This binding mechanism is central to the drug’s effectiveness, creating a continuous barrier in new skin, hair, and nail growth, facilitating the gradual replacement of infected tissue with healthy, drug-protected tissue over time.

What side effects are possible with Griseovin?

Possible Side Effects and Safety Information

The official safety profile for Griseovin (Griseofulvin) categorizes potential adverse reactions according to frequency and the body system affected, as established by regulatory authorities. Reactions frequently observed, often categorized as Common, include headache (which may disappear with continued use), nausea, vomiting, and diarrhea.

System-Organ-Class Groupings

Adverse effects are formally grouped into categories such as Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions

The regulatory labeling documents risks that are rare but clinically significant. These Serious Adverse Reactions include hepatotoxicity (severe liver injury), severe skin conditions like Toxic Epidermal Necrolysis and Erythema Multiforme, and blood dyscrasias such as leukopenia. Periodic monitoring of renal, hepatic, and hematopoietic function is recommended during prolonged treatment.

Population-Specific Safety Restrictions

Griseovin is formally contraindicated in specific patient groups based on regulatory findings. It must not be used by pregnant patients due to the risk of harm to the fetus. It is also contraindicated in individuals with severe hepatic failure or a history of Porphyria. Furthermore, the drug may reduce the efficacy of oral contraceptives, and patients are advised regarding potential photosensitivity reactions, requiring avoidance of excessive sunlight exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Griseovin (Griseofulvin) overdose is defined by the risk of severe systemic toxicities that require immediate intervention. Overdosage may initially manifest with acute clinical signs that include gastrointestinal effects (nausea, vomiting, diarrhea) and CNS symptoms (headache, dizziness, mental confusion).

Urgent Medical Attention Required

Immediate medical attention must be sought for the emergence of any severe reaction or symptom indicative of serious toxicity. Of critical concern are life-threatening manifestations such as severe liver injury (hepatotoxicity), which has been associated with fatalities, and severe cutaneous reactions (e.g., Stevens-Johnson syndrome). The medication must be immediately discontinued upon the occurrence of these serious adverse events.

Supportive Management and Constraints

In the event of overdosage, symptomatic and supportive treatment is advised. Management procedures may involve steps to reduce drug absorption, such as gastric lavage or the administration of activated charcoal. Regulatory documents note that no specific antidote is known for this drug, and it is considered poorly dialyzable. Monitoring of hepatic function and complete blood count is required to detect potential damage to the hepatic and hematologic systems.

Therapeutic Uses of Griseovin

What Griseovin Treats: Main Uses and Benefits

Griseovin (Griseofulvin) is generally considered relevant for managing conditions characterized by periods of heightened symptoms related to fungal infections of keratinized tissues. The medication is applied for treating dermatophyte infections of the skin, hair, and nails, including Tinea corporis (body ringworm), Tinea capitis (scalp ringworm), and Tinea unguium (nail fungus).

It is applied across domains where additional symptomatic support is needed because the fungal infection is deeply seated or widespread, and is applied in scenarios where short-term symptomatic assistance is needed. The medication helps address symptom clusters that may become intense or disruptive, such as persistent itching, scaling, and the structural changes to the hair or nails. This systemic approach may assist with maintaining functional stability and contributes to the growth of healthier tissue.

For chronic infections, Griseovin is relevant for easing symptoms that interfere with daily comfort. It supports the patient during difficult episodes by easing distress and contributes to improved comfort and overall well-being.


Quick Fact: Relief for Persistent Fungal Symptoms
Primary Focus Fungal infections presenting with systemic or localized discomfort.
Typical Scenario Applied in clinical settings that involve acute or unstable symptom patterns (e.g., deeply rooted infection).
Key Symptom Axes Symptoms related to inflammatory or irritative states (e.g., persistent itching, scaling).
Benefit Provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH DailyMed Labeling

Eligibility and Restrictions for Use

Eligibility for Griseovin (Griseofulvin) — Official Regulatory Information

Regulatory documents strictly define patient eligibility for Griseovin (griseofulvin) via absolute exclusions and mandated restrictions.

Contraindicated Populations Key Eligibility Restrictions
Pregnancy: Absolutely prohibited in women who are pregnant or may become pregnant during treatment. Women of Childbearing Age: Must use effective contraception during treatment and for a specific period (e.g., 4 weeks) after the last dose.
Porphyria or Hepatocellular Failure: Prohibited in patients with severe liver disease or porphyria. Sexually Active Males: Must use an effective barrier contraceptive during therapy and for a specific period (e.g., 6 months) after cessation.
Hypersensitivity: Patients with known allergy to griseofulvin or its components. Pediatric Use: Safety and efficacy are generally not established for children 2 years of age and younger (for ultramicrosize formulations).

Use is also not recommended in patients with Systemic Lupus Erythematosus (SLE) as the condition may be exacerbated. While no dosage adjustment is required for renal impairment, patients with less severe hepatic impairment require cautious use and regular monitoring of liver function. For breastfeeding, the safety is not established, and use is often contraindicated or requires cessation of nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Griseovin (Griseofulvin) interacts with several medicinal products and substances, primarily due to its activity as a hepatic enzyme inducer and its unique absorption requirements.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Interaction Effect and Regulatory Requirement
Oral Contraceptives (Estrogen-containing) Griseofulvin may reduce the effectiveness, potentially causing contraceptive failure. An alternate or additional, reliable method of contraception is required during and for a period after treatment.
Anticoagulants (Warfarin-type) Griseofulvin reduces the anticoagulant effect, necessitating increased monitoring (e.g., INR) and possible dosage adjustment of the anticoagulant during and after Griseofulvin therapy.
Barbiturates (e.g., Phenobarbital) Barbiturates accelerate Griseofulvin's metabolism, reducing its plasma levels and activity. Increased Griseofulvin dosage may be required.
Alcohol (Ethanol) Concomitant consumption may result in a severe, rapid adverse reaction, potentially mimicking a disulfiram reaction. Avoidance of alcohol is necessary.

Absorption and Food Constraints

To ensure adequate systemic exposure, Griseofulvin absorption is enhanced significantly when the drug is taken with a fatty meal or milk. Administration with food is necessary for effective therapeutic action.

Population-Specific Constraints

Female patients of reproductive potential must use contraception during treatment and for four weeks following the last dose. Male patients should not father children during treatment and for six months following the last dose.

Mechanism of Action

The mechanism of action for Griseovin (Griseofulvin) is characterized by a two-pronged approach that targets the fungal cell's ability to divide and induces the formation of an antifungal barrier within the host's tissue.

Inhibition of Fungal Cell Mitosis

Griseofulvin acts as a fungistatic agent by binding to microtubular proteins (α- and β-tubulin) inside susceptible dermatophytes. This binding prevents the assembly of microtubules, which are essential for forming the mitotic spindle. By disrupting this critical structure, the drug arrests the fungal cell division pathway, which limits organism proliferation.

xD83D️ Physiological Shielding via Keratin Deposition

This systemic domain explains the drug's physiological delivery and action. After absorption, Griseofulvin exhibits a high affinity for keratin precursor cells (keratinocytes) and is tightly incorporated into the newly synthesized keratin of the skin, hair, and nails. This results in a keratin layer containing sequestered drug, which resists fungal colonization. The resulting physiological effect is achieved as the older, infected keratin is gradually replaced, and this process facilitates the physical exfoliation of the older, infected keratin.

Dosage and Administration Information

How Griseovin is Used in Clinical Practice

Griseovin (Griseofulvin) is a systemic antifungal agent used to treat dermatophyte infections of the hair, skin, and nails. Its use is guided by established clinical parameters concerning the administration route, precise dosing based on formulation, and required treatment duration.


Official Dosing and Administration

The sole approved route of administration for Griseovin is Oral (by mouth). The medication is available as Tablets (Microsize and Ultramicrosize formulations) and an Oral Suspension.

Standard Labeled Dosing Regimens

Formulation Indication / Infection Type Typical Adult Daily Dose Range
Microsize Less difficult infections (e.g., Tinea corporis) 500 mg
Microsize More difficult infections (e.g., Tinea unguium) 750 mg to 1,000 mg
Ultramicrosize Less difficult infections 330 mg to 375 mg

Dosage may be taken once daily or in divided doses.


Contextual and Duration Requirements

Administration Conditions

Griseofulvin must be taken with or immediately after a meal, specifically a high-fat meal (such as whole milk), as this significantly enhances the drug's absorption. The oral suspension must be shaken well before use. Some Ultramicrosize tablets can be crushed and mixed with applesauce for immediate consumption.

Treatment Duration

Treatment duration is prolonged and depends on the rate of replacement of infected keratinized tissue with healthy tissue:

  • Tinea capitis: 4 to 12 weeks.
  • Tinea unguium (Nails): 4 to 12 months or longer.

Treatment should be continued for at least two weeks after all signs of infection have disappeared. For pediatric patients, dosing is weight-based (e.g., approximately 10 mg/kg per day for Microsize formulations).

Recent Clinical Evidence

Griseovin: Recent Clinical Evidence

Research Methodology

Studies suggest Griseovin may act by modulating certain biological pathways. The research base includes a number of randomized controlled trials (RCTs) and open-label extension studies. Clinical trials have investigated whether the drug is associated with changes in symptoms and quality of life over treatment periods ranging from 12 weeks to over a year.

Key Findings from Clinical Trials

Investigating Changes in Symptom Severity

Multiple Phase 3 clinical trials have investigated whether the drug is associated with changes in symptom severity, measured using standardized rating scales. Monotherapy studies evaluated whether the drug was associated with a greater reduction in symptom scores compared to placebo after 12 weeks. Combination therapy studies compared the use of combination therapy versus monotherapy and examined changes in symptom severity over a 24-week period. The findings evaluated whether there was a greater change in scores with the combination regimen.

Assessing Quality of Life Measures

Research has explored whether the treatment is associated with improvements in patient-reported quality of life (QoL) and daily functioning. One study that followed participants for 52 weeks assessed the drug's impact on the ability to perform activities of daily living and overall self-rated QoL scores. The research evaluated whether patients using the drug regimen were associated with better QoL scores compared to the control group.

Safety and Tolerability Profile

Clinical data has been used to assess the potential tolerability profile, including common and serious adverse events. Common Adverse Events (AEs) reported in trials included headache, nausea, and localized reactions. These generally occurred early in the treatment course and were often reported as temporary. Studies have typically evaluated a starting regimen of X mg once daily, with the option to escalate the dose to Y mg after 4 weeks. The evidence describes the drug as a studied option for the condition, based on the findings from multiple clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Griseovin (FAQ)


Q: What are the most commonly reported side effects of Griseovin?

According to official prescribing information, commonly reported side effects include headache, which some reports suggest may lessen with continued use, and gastrointestinal upset such as nausea, vomiting, or diarrhea. Less frequently reported effects can include fatigue or dizziness.


Q: Can Griseovin cause stomach problems or nausea?

Yes, official sources indicate that gastrointestinal upset is a common side effect of this medicine. Issues such as nausea, vomiting, diarrhea, and a general upset stomach have all been reported.


Q: Does Griseovin interact with common pain relievers?

Official interaction databases drawing from regulatory data indicate potential interactions with certain common pain relievers. Specifically, the activity of the drug and substances like acetaminophen may be affected, which may require careful monitoring.


Q: Is Griseovin safe to use if I have liver issues?

Official regulatory information states that this medicine is contraindicated in patients who have pre-existing conditions such as hepatocellular failure (severe liver failure). This means that the use of the medicine is restricted or prohibited in such cases.


Q: Is Griseovin available over the counter, or is it prescription only?

Griseovin is classified as a prescription-only medication, often marked with 'Rx only' on its labeling. This means it can only be legally dispensed by a pharmacist with a valid prescription.


Q: Do food or supplements affect how Griseovin works?

Yes, food significantly affects the drug's absorption. Regulatory information states that Griseofulvin absorption is greatly enhanced when taken with or immediately after a high-fat meal or milk. Furthermore, the medicine may also affect the activity of certain vitamins, such as Vitamin A and Vitamin D.


Q: Can Griseovin make me more sensitive to sunlight?

Official warnings describe that a photosensitivity reaction is occasionally associated with Griseofulvin therapy. For this reason, official warnings state that caution regarding intense natural or artificial sun exposure is warranted.


Q: Is it common to feel dizzy or lightheaded while taking Griseovin?

Dizziness and fatigue have been reported among the less common side effects listed in the regulatory documents. If these effects occur, they may be a factor to consider when performing routine activities.


Q: Are there any long-term health concerns linked to using Griseovin?

Because Griseofulvin treatment is often prolonged, official warnings state that periodic monitoring of organ function (liver, kidney, and blood systems) is recommended. Additionally, regulatory documents reference animal toxicology studies where long-term, high-dose use resulted in tumor development in certain strains of mice and rats.


Q: How quickly do people typically start seeing results with Griseovin?

Improvement is generally gradual because the drug works by incorporating into newly synthesized keratin (the substance that makes up skin, hair, and nails). Results become visible only as the older, infected tissue is replaced by this new, healthy tissue. This process naturally takes time.


Q: Does Griseovin have a black box warning in the US?

The official FDA prescribing information for Griseofulvin does not contain an FDA Black Box Warning. A Black Box Warning is the strongest safety warning that the FDA requires on the labeling of prescription medicines.


Q: What is the risk of an allergic reaction to Griseovin?

Rash and hives are commonly reported allergic reactions associated with the medicine. However, official warnings also describe rare but serious adverse reactions, including severe skin conditions like Stevens-Johnson syndrome.


Q: Does Griseovin impact the ability to drive or operate machinery?

Adverse effects reported in regulatory documents include dizziness, mental confusion, and impairment of performance of routine activities. These effects may affect an individual’s ability to safely drive a vehicle or operate machinery.


Q: Why is monitoring sometimes required during Griseovin treatment?

For patients receiving prolonged therapy, periodic monitoring of organ system function is recommended in the official safety information. This typically includes the renal (kidney), hepatic (liver), and hematopoietic (blood) systems.


Q: Are there specific vitamins or minerals that interact with Griseovin?

Official sources describe potential interactions with certain vitamins, such as Vitamin A and Vitamin D. These effects may require monitoring during the course of treatment.


Q: What is the general safety classification of Griseovin (e.g., in pregnancy categories)?

Griseofulvin is contraindicated in women who are or may become pregnant during treatment, due to reports of fetal harm. It was historically designated as Pregnancy Category X, which signifies a clear risk that outweighs any potential benefit.


Q: Can Griseovin affect the kidneys?

While not common, rare adverse reactions involving the kidneys have been reported in the official prescribing information, such as proteinuria (protein in urine) and nephrosis. For this reason, periodic renal function monitoring is included in the guidelines for prolonged use.


Q: Is it normal to experience a rash while using Griseovin?

Skin issues such as rash and hives (urticaria) are commonly reported adverse reactions associated with the medicine. These are often described as hypersensitivity-type reactions.


Q: Are there common mental or mood changes associated with Griseovin?

Adverse effects reported include insomnia (difficulty sleeping). Rarely, mental confusion or psychotic symptoms have been associated with large doses or extended therapy, according to regulatory reports.


Q: Does Griseovin interact with supplements like St. John's Wort?

Griseofulvin is described as a hepatic enzyme inducer, meaning it speeds up the breakdown of some substances in the body. Other substances with the same effect, such as the herbal supplement St. John's Wort, may be associated with potential interactions.


Q: Is Griseovin considered a 'broad spectrum' antifungal?

Regulatory information indicates that Griseofulvin is effective only against specific types of fungi called dermatophytes (such as Tinea species). It is specifically described as being not effective against other fungal infections like Candidiasis or Histoplasmosis.


Q: Can Griseovin be taken by individuals who are lactose intolerant?

Official drug descriptions state that the tablets contain lactose (monohydrate or anhydrous) as an inactive ingredient. Individuals who cannot tolerate lactose should be aware of this component in the formulation.


Q: Does Griseovin affect the immune system?

Regulatory reports include rare instances of effects on the blood, such as leukopenia (reduced white blood cells). Additionally, the official warnings mention descriptions of a lupus-like syndrome or worsening of existing lupus.


Q: Is it safe to use Griseovin while breastfeeding (descriptive only)?

Official information states that it is unknown if the drug is excreted in breast milk and that safety has not been established during breastfeeding.


Q: What are the most serious, but rare, side effects noted in official reports?

Official warnings describe rare but serious adverse reactions, including severe skin conditions (e.g., Stevens-Johnson syndrome), liver toxicity (hepatotoxicity), and effects on the blood (e.g., leukopenia).


Q: Are there any lifestyle changes recommended while taking Griseovin?

Official prescribing information indicates three key constraints for patients: alcohol should be avoided during treatment, specific contraceptive requirements are necessary for patients of reproductive potential, and the drug must be taken with a fatty meal for proper absorption.

How should Griseovin be stored and disposed of?

Griseovin (Griseofulvin) must be stored strictly according to regulatory standards to maintain its stability. Tablets and oral suspension should be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from light and excess moisture and must not be frozen.

The product must remain in its original container, which should be kept tightly closed and stored out of the sight and reach of children.

For disposal, unused or expired Griseofulvin should be handled in accordance with local regulations. Official guidance recommends using a medicine take-back program and specifies that the medicine must not be flushed down the toilet or disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Griseovin found in:

A-Z Index: